Hainan Honz Pharmaceutical Co Total Liabilities
Hainan Honz Pharmaceutical Co total liabilities. Based on the latest financial reports, Hainan Honz Pharmaceutical Co (300086) has total liabilities worth CN¥824.00 Million CNY (≈ $120.58 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 300086 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Hainan Honz Pharmaceutical Co (2007–2025)
Total liabilities of Hainan Honz Pharmaceutical Co from 2007 to 2025. This chart illustrates how Hainan Honz Pharmaceutical Co's total liabilities have evolved over time, based on quarterly financial data.
Hainan Honz Pharmaceutical Co Competitors by Total Liabilities
The table below lists competitors of Hainan Honz Pharmaceutical Co ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ABC arbitrage SA
PA:ABCA
|
France | €15.48 Million |
|
International CSRC Investment Holdings Co Ltd
TW:2104
|
Taiwan | NT$22.94 Billion |
|
Hanyang ENG Co. Ltd
KQ:045100
|
Korea | ₩287.67 Billion |
|
JTL Industries Ltd
NSE:JTLIND
|
India | Rs4.75 Billion |
|
Tanzanian Royalty Exploration Corp
NYSE MKT:TRX
|
USA | $76.66 Million |
|
Shenzhen Longood Intelligent Electric Co Ltd Class A
SHE:300543
|
China | CN¥749.91 Million |
|
Itcen Co. Ltd
KQ:124500
|
Korea | ₩850.59 Billion |
|
Lontrue Co Ltd
SHE:300175
|
China | CN¥56.18 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Hainan Honz Pharmaceutical Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 300086 total assets.
Liquidity & Leverage Metrics
Hainan Honz Pharmaceutical Co Total Liabilities Ratios Explained
Hainan Honz Pharmaceutical Co total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.95 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hainan Honz Pharmaceutical Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hainan Honz Pharmaceutical Co (2007–2025)
The table below shows the annual total liabilities of Hainan Honz Pharmaceutical Co from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥869.79 Million ≈ $127.28 Million |
+7.31% |
| 2024-12-31 | CN¥810.53 Million ≈ $118.61 Million |
+2.91% |
| 2023-12-31 | CN¥787.60 Million ≈ $115.25 Million |
-15.58% |
| 2022-12-31 | CN¥932.96 Million ≈ $136.52 Million |
+3.07% |
| 2021-12-31 | CN¥905.14 Million ≈ $132.45 Million |
-10.55% |
| 2020-12-31 | CN¥1.01 Billion ≈ $148.08 Million |
+70.76% |
| 2019-12-31 | CN¥592.59 Million ≈ $86.72 Million |
+12.47% |
| 2018-12-31 | CN¥526.90 Million ≈ $77.10 Million |
+67.10% |
| 2017-12-31 | CN¥315.31 Million ≈ $46.14 Million |
-0.48% |
| 2016-12-31 | CN¥316.83 Million ≈ $46.36 Million |
+27.63% |
| 2015-12-31 | CN¥248.25 Million ≈ $36.33 Million |
+102.67% |
| 2014-12-31 | CN¥122.49 Million ≈ $17.92 Million |
+29.80% |
| 2013-12-31 | CN¥94.36 Million ≈ $13.81 Million |
-0.70% |
| 2012-12-31 | CN¥95.02 Million ≈ $13.91 Million |
-14.22% |
| 2011-12-31 | CN¥110.77 Million ≈ $16.21 Million |
+45.73% |
| 2010-12-31 | CN¥76.01 Million ≈ $11.12 Million |
+41.83% |
| 2009-12-31 | CN¥53.60 Million ≈ $7.84 Million |
-4.17% |
| 2008-12-31 | CN¥55.93 Million ≈ $8.18 Million |
+117.75% |
| 2007-12-31 | CN¥25.68 Million ≈ $3.76 Million |
-- |
About Hainan Honz Pharmaceutical Co
Honz Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pediatric medicines in China and internationally. It operates through Pharmaceutical Manufacturing and Sales; and Daily Necessities Manufacturing and Sales segments. The company offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal, cough … Read more